AGO2 (Argonaute-2)

Introduction

AGO2 encodes Argonaute-2, the catalytic component of the microRNA-induced silencing complex (miRISC). Unlike other Argonaute proteins, AGO2 possesses endonuclease (slicing) activity that can directly cleave perfectly complementary mRNA targets. AGO2 is essential for miRNA-mediated gene silencing and has been implicated in various neurological disorders including Alzheimer’s disease, Parkinson’s disease, and ALS. This page covers AGO2 structure, function, disease associations, and therapeutic potential. ^{1Metallothionein in neurodegeneration (1995)1995 · PMID 8543772Open reference}

Overview

flowchart TD
    AGO2["AGO2"] -->|"regulates"| STAT3["STAT3"]
    AGO2["AGO2"] -->|"activates"| PTEN["PTEN"]
    AGO2["AGO2"] -->|"inhibits"| Cancer["Cancer"]
    AGO2["AGO2"] -->|"inhibits"| Lymphoma["Lymphoma"]
    AGO2["AGO2"] -->|"inhibits"| Ms["Ms"]
    AGO2["AGO2"] -->|"inhibits"| Tumor["Tumor"]
    AGO2["AGO2"] -->|"regulates"| Ms["Ms"]
    AGO2["AGO2"] -->|"regulates"| Tumor["Tumor"]
    AGO2["AGO2"] -->|"activates"| Als["Als"]
    AGO2["AGO2"] -->|"activates"| Depression["Depression"]
    AGO2["AGO2"] -->|"therapeutic target"| Breast_Cancer["Breast Cancer"]
    AGO2["AGO2"] -->|"therapeutic target"| Cancer["Cancer"]
    AGO2["AGO2"] -->|"therapeutic target"| Als["Als"]
    AGO2["AGO2"] -->|"inhibits"| Gastric_Cancer["Gastric Cancer"]
    style AGO2 fill:#4fc3f7,stroke:#333,color:#000

Structure and Mechanism

Domain Architecture

AGO2 contains the same domain structure as other Ago proteins:

1. N-terminal domain: Mediates interactions and target recognition

2. PAZ domain: Binds 3’ end of miRNA

3. MID domain: Binds 5’ phosphate of miRNA

4. PIWI domain: Catalytic center with RNase H-like fold

The critical difference is that AGO2 has an intact catalytic DEDH tetrad (Asp-Asp-Glu-His) in its PIWI domain, enabling it to cleave (slice) perfectly matched targets.

Slicing Activity

AGO2 is the only catalytically active human Argonaute:

• Can directly cleave perfectly complementary mRNA targets

• This “slicing” activity leads to mRNA degradation

• Required for some miRNA-mediated silencing pathways

Normal Physiological Functions

miRNA-Mediated Silencing

AGO2 is central to miRNA function:

• Primary mediator of miRNA-guided mRNA cleavage

• Also mediates translational repression

• Essential for development and cellular function

Synaptic Function

In neurons:

• Regulates local protein synthesis at synapses

• Controls dendritic spine morphology

• Important for synaptic plasticity

Brain Development

AGO2 is essential for:

• Neuronal differentiation

• Axon guidance

• Cortical development

Disease Associations

Alzheimer’s Disease

AGO2 in AD:

• Dysregulated in AD brain

• Regulates APP and BACE1 expression

• Affected by AD-associated stress responses

• Some variants modify AD risk

Parkinson’s Disease

In PD:

• Regulates LRRK2 and α-synuclein expression

• Dysregulated miRNA-AGO2 pathways in PD

• May influence dopaminergic neuron survival

ALS

In ALS:

• AGO2 is sequestered into stress granules in ALS

• TDP-43 pathology affects AGO2 function

• Dysregulation contributes to motor neuron degeneration

Cancer

AGO2 is frequently upregulated in cancers:

• Promotes tumor progression

• Enhances cell proliferation

• Regulates oncogenes and tumor suppressors

Expression

Key Publications

1. He et al., Argonaute proteins in neurodegeneration (2024)

2. Huang et al., AGO2 in Alzheimer’s disease (2021)

3. Gasri-Plotnitsky et al., Argonaute and ALS (2019)

Therapeutic Potential

AGO2 is a therapeutic target:

• siRNA delivery: AGO2 is exploited for therapeutic gene silencing

• miRNA modulators: miRNA mimics/antagomirs affect AGO2 function

• Small molecules: Modulate miRISC loading

• Gene therapy: Deliver specific miRNAs targeting disease genes

Cross-References

• AGO1 — Argonaute-1

• DICER1 — MicroRNA processing

• TARDBP — TDP-43

• FUS — FUS protein

• MicroRNA — Small non-coding RNAs

• Synaptic Plasticity — Synaptic function

• Alzheimer’s Disease — AD mechanisms

• Parkinson’s Disease — PD mechanisms

External Links

• National Institute on Aging (NIA)

• Alzheimer’s Association

• Michael J. Fox Foundation for Parkinson’s Research

• ALS Association

• Cure Huntington’s Disease Initiative (CHDI)

• National Institute on Neurological Disorders and Stroke (NINDS)